Q2 2025 Anika Therapeutics Inc Earnings Call Transcript
Key Points
- Anika Therapeutics Inc (ANIK) reported that their regenerative solutions revenue grew by 41% this quarter, driven by the strong performance of the Integrity implant system.
- The company successfully resolved production challenges earlier in the quarter, restoring output to historic levels without delaying deliveries to patients.
- Anika Therapeutics Inc (ANIK) maintained its full-year 2025 guidance, indicating confidence in meeting its financial targets.
- The company plans to submit the third and final PMA module for Hyalofast on schedule, with a commercial timeline extended to 2027 to ensure thorough FDA review.
- Anika Therapeutics Inc (ANIK) has no debt and ended the second quarter with $53 million in cash, indicating strong liquidity.
- The Hyalofast clinical trial missed its pre-specified co-primary endpoints, impacting the statistical significance of the study results.
- Revenue in the quarter was down 8%, with the OEM channel declining by 13% due to continued pressure on demand and pricing.
- Gross margin decreased to 51%, down 16 percentage points from the same period last year, primarily due to a one-time $3 million charge related to lower production yields.
- The company anticipates a 12-month delay in the launch timing of Hyalofast, affecting long-term revenue guidance for the commercial channel.
- Adjusted EBITDA from continuing operations was negative $200,000 in the second quarter, a decline of $4.9 million compared to the same period in 2024.
Good morning, ladies and gentlemen, and welcome to Anika's second-quarter earnings conference call. I will now turn the call over to Matt Hall, director of corporate Development and Investor relations.
Please proceed. (Operator Instructions)
Thank you.
Good morning and thank you for joining us for Anika's second-quarter 2025 conference call and webcast. I am Matt Hall, Anika's director of corporate development investor relations. Our earnings press release was issued earlier this morning and is available on our investor relations website located at www. Anika.com, as are the supplementary PowerPoint slides that will be used for the discussion today.
With me on the call are Dr. Cheryl Blanchard, President and Chief Executive Officer, and Steve Griffin, executive Vice President, Chief Financial Officer and Chief Operating Officer, who will present our second- quarter 2025 financial results and business highlights.
Please take a moment
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
